Farviron

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Farviron

What is Farviron? Defining the Systemic Antifungal

Property Description
Active ingredient Fluconazole
Form Tablet, Oral Suspension, Solution for Injection
Pharmacological class Triazole Antifungal
Common use Systemic Fungal and Yeast Infections
Origin Synthetic Compound

What Type of Medicine is Farviron?

Farviron is a prescription-only medication primarily used to manage and resolve infections caused by fungi and yeasts throughout the body. Its active ingredient is Fluconazole, a substance classified as a synthetic systemic antifungal agent. This drug belongs to the azole antifungal class of medicines, more specifically categorized as a triazole derivative.

The triazole classification is based on the chemical structure of Fluconazole, which is a synthetic small molecule. Pharmacological studies confirmed its categorization and established fungistatic activity against a range of fungal pathogens, providing the foundation for its therapeutic application. Being a systemic antifungal, the medicine is designed to be absorbed into the bloodstream and distributed throughout the body, making it a clinically recognized solution for widespread internal fungal issues.


Forms, Composition, and General Purpose

Farviron (Fluconazole) is supplied in several pharmaceutical preparations to ensure effective delivery, supporting both oral and intravenous (IV) administration. The available dosage form(s) typically include the tablet, the oral suspension, and the solution for injection. This versatility allows for administration across various clinical needs, from outpatient care using the oral tablet to settings requiring the IV solution.

The drug's composition is consistently a single active ingredient product (monotherapy), containing only Fluconazole as the therapeutic substance. Research has analyzed the efficacy of Fluconazole’s fungistatic action across various patient scenarios. This confirms the primary function of this medication is to relieve and resolve symptomatic conditions by halting the growth and spread of problematic fungal organisms.

What side effects are possible with Farviron?

Official Regulatory Profile of Possible Side Effects

The safety profile of Farviron (Fluconazole) is documented in official government regulatory documents, which classify adverse reactions primarily by frequency and the body system affected.

Classification Example Adverse Reaction (Based on Labeling)
Very Common Headache
Common Nausea, Vomiting, Diarrhea, Abdominal pain, Transient elevations in liver enzymes, Rash

Adverse reactions are grouped into system-organ classes, including Gastrointestinal disorders, Nervous system disorders, Hepatobiliary disorders, and Skin and subcutaneous tissue disorders.

Serious Adverse Reactions and Safety Constraints

Official labeling describes certain reactions as rare but clinically important. These serious adverse reactions include serious hepatic toxicity (e.g., hepatic failure), severe cutaneous reactions (e.g., Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis), and cardiovascular effects (e.g., QT prolongation and Torsade de pointes). The risk of a serious skin reaction is documented as being higher in patients with deep-seated fungal infections.

Regarding population-specific safety, caution is noted for use in individuals with renal impairment, as the drug's clearance depends heavily on kidney function. Official documents explicitly state a safety restriction where co-administration with specific drugs that prolong the QT interval and are metabolized by the CYP3A4 enzyme (such as cisapride) is contraindicated due to the potential for cardiotoxicity. High-dose, long-term use in the first trimester of pregnancy has been associated with birth defects.

Overdose and Emergency Response

Overdose Scope

Documented overdose presentations: Acute overdose has been associated with specific neuropsychiatric manifestations, including hallucination and paranoid behavior.

Physiological systems affected (as stated in label): The Central Nervous System (CNS) is affected. The Cardiovascular System is at risk for severe arrhythmia, including QT prolongation and Torsades de pointes. Severe hepatic toxicity is also a documented outcome.

Dose-related or exposure-related factors (if applicable): Exposure from an overdose results in toxic concentrations that may be reduced by specific procedural intervention.

Population-specific overdose notes (if applicable): The drug’s clearance is primarily renal, and thus is significantly affected by impaired renal function. Neonates exhibit a considerably longer plasma half-life than adults due to renal immaturity, which is a factor in managing potential toxicity.

Emergency-response statements (as written in official documents): Symptomatic treatment and supportive measures should be instituted. Gastric lavage may be considered if clinically indicated. Hemodialysis is an officially described procedure that reduces plasma concentrations.

When immediate medical help is required (label-derived phrasing only): Immediate medical attention is required for any suspected overdose or the manifestation of severe life-threatening symptoms.


Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The overdose profile involves the risk of serious and life-threatening outcomes, particularly related to cardiac function.

Regulatory basis (EMA / FDA / etc.): The documented information is derived from official regulatory prescribing information (e.g., FDA Labeling and EMA/SmPC post-marketing data).

Overdose-context constraints (as defined in official documents): Management is constrained by the absence of a specific antidote, necessitating reliance on supportive care.


Resulting overdose structure

Official overdose statements:

  • Overdose is documented with hallucination and paranoid behavior.
  • The risk of QT prolongation and Torsades de pointes is a severe documented outcome.
  • Management requires symptomatic treatment and supportive measures.
  • Hemodialysis can reduce plasma concentration by approximately 50%.
  • Immediate medical help is mandatory for any suspected overdose.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Farviron overdose profile by documenting specific neuropsychiatric and potentially life-threatening cardiac manifestations that necessitate immediate professional medical intervention. The official guidance requires the institution of supportive measures and notes the efficacy of hemodialysis as a procedural means of clearance, reflecting a management strategy focused on mitigating severe clinical outcomes in the absence of a specific reversing agent.

Therapeutic Uses of Farviron

Farviron (Fluconazole) is a systemic antifungal medication primarily used for managing a range of infections caused by fungi and yeasts, applied in addressing symptoms related to localized discomfort or systemic imbalance. It is generally indicated for serious fungal infections and for prophylactic use. The main therapeutic goal is managing symptomatic conditions and providing supportive relief in high-risk scenarios.


Targeting Systemic and Life-Threatening Fungal Disease

This domain covers conditions marked by increased physiological stress, such as those where the fungal organism has entered the bloodstream (Candidemia) or central nervous system, like Cryptococcal Meningitis. Farviron is commonly used to help manage symptoms like fever, systemic illness, and the intense headache associated with neurological fungal involvement. The key benefit is that the medication assists with managing the systemic infection and supports maintenance therapy, which may assist in reducing the likelihood of relapse in serious, pervasive diseases in vulnerable individuals.


Relieving Mucosal and Recurrent Yeast Infections

This application is relevant in conditions characterized by periods of heightened symptoms of the mucous membranes and genital tract, including oral thrush and recurrent vaginal yeast infections. It is applied in addressing symptom clusters that may become intense or disruptive, such as severe itching, burning, and pain on swallowing (dysphagia). The medication contributes to improved comfort during symptomatic periods and may help manage recurrent manifestations, which assists with maintaining functional stability.


Key Use Contexts: Farviron is commonly used for managing conditions such as systemic and mucosal candidiasis, Cryptococcal meningitis, and to provide supportive management to reduce the risk of fungal disease in high-risk groups.

Focus on Mucosal Discomfort: The medication is applied to ease symptoms related to inflammatory or irritative states on surfaces like the mouth and throat, contributing to physical comfort during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Farviron?

Farviron (Fluconazole) eligibility is defined by regulatory bodies through specific contraindications and required cautions based on patient populations.

The medicine is strictly contraindicated for individuals with known hypersensitivity to fluconazole or any related azole antifungal agent. It is also prohibited for patients receiving certain concomitant drugs known to prolong the QT interval and metabolized by the CYP3 A4 enzyme, such as pimozide or quinidine. Additionally, specific oral formulations are contraindicated in patients with rare hereditary disorders involving sugar malabsorption, due to excipients like lactose or sucrose.

Adults and children 6 months and older are the primary eligible age groups for established indications. Caution is necessary for older adults due to potential age-related reductions in kidney function. Conditional use applies to patients with impaired renal function, which necessitates a dose adjustment, and those with liver dysfunction or cardiovascular conditions (like pre-existing QT prolongation) who require close monitoring. Pregnancy generally defines a not recommended status, except in severe, life-threatening infections where the benefit outweighs the risk. Caution is also advised during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Farviron (Fluconazole) can interact with many other medicines primarily by affecting the metabolism of co-administered drugs. It is a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4, which are liver enzymes responsible for drug clearance.


Contraindicated Combinations

Co-administration of Farviron is contraindicated with certain medicines that are metabolized by CYP3A4 and are known to prolong the QT interval, increasing the risk of serious heart rhythm abnormalities. These include Cisapride, Astemizole, Pimozide, Quinidine, and Erythromycin. The use of Terfenadine is also contraindicated when Farviron is administered at doses of 400 mg per day or higher.


Significant Drug-Drug Interactions

Interactions often result in increased plasma concentrations of the co-administered drug. Medications that may require close monitoring or dose adjustment when taken with Farviron include:

  • Anticoagulants (e.g., Warfarin) ightarrow Increased risk of bleeding.
  • Immunosuppressants (e.g., Cyclosporine, Tacrolimus) ightarrow Increased exposure to the immunosuppressant.
  • NSAIDs (e.g., Celecoxib) ightarrow Increased NSAID exposure.
  • Rifampicin, an enzyme inducer, significantly decreases Farviron concentrations.
  • Concomitant use with Hydrochlorothiazide increases Farviron exposure.

Pharmacodynamic Interactions

Farviron increases the risk of QT prolongation when used with other agents that share this effect, such as Amiodarone or Halofantrine.

Mechanism of Action

Targeted Inhibition of Fungal Enzyme Systems

Farviron (Fluconazole) inhibits key enzymatic processes in the fungal cell's fundamental structures. The mechanism relies on targeted blockade of Cytochrome P450 14alpha-demethylase (C14alpha-demethylase), a fungal enzyme essential for synthesizing the cell membrane component, ergosterol. This selective binding prevents the enzyme from completing a required step in the fungal biosynthetic pathway, initiating a sequence of cellular dysfunction.

Mechanistic Cascade to Membrane Failure

By inhibiting the enzyme, Fluconazole causes a critical depletion of ergosterol and a harmful accumulation of toxic 14alpha-methylated sterols within the fungal cell. This disruption structurally compromises the cell membrane, resulting in increased permeability and loss of cellular integrity, which produces the physiological effect of inhibiting fungal cell growth (fungistasis).

Biological Constraints on Mechanistic Efficacy

The mechanism is constrained by fungal resistance processes, including mutations in the ERG11 gene, which alter target binding, or the overexpression of efflux pumps (transporter proteins) that reduce intracellular Fluconazole concentration at the site of action.

Dosage and Administration Information

How to Use Farviron: Official Administration Guidelines

Farviron (Fluconazole) is administered according to standardized protocols, focusing strictly on approved routes, dose ranges, and timing. The medication is officially supplied for both Oral (tablet, suspension) and Intravenous (IV) Infusion administration.


Dosing and Frequency Principles

Most multi-day regimens begin with a specific Loading Dose (typically double the maintenance dose) administered on Day 1 to achieve rapid systemic levels. Following this, the dose transitions to the lower Maintenance Dose, which is typically taken once daily. For certain superficial conditions or prophylaxis against relapse, the schedule may be once weekly or a single oral dose of 150 mg.


Administration Logistics and Adjustments

Category Procedural Rule
Food Relationship May be taken with or without food.
IV Infusion Rate Must not exceed 10 mL/minute (approx. 200 mg/hour for the 2 mg/mL solution).
Renal Impairment Dose reduction of 50% is required for the maintenance dose in adults with Creatinine Clearance le 50 mL/min.
Pediatric Dosing Dosing is calculated using mg/kg and is often administered at prolonged intervals in neonates due to slower clearance.
Missed Dose If a dose is missed, take it as soon as remembered unless it is near the next scheduled dose; do not double the dose.

The official instructions mandate these specific protocols, which define the correct and standardized use of the medication based on the patient's condition and physiological state.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Farviron

Evidence for Use in Systemic and Invasive Fungal Disease

This section will summarize the types of research available, such as short-term clinical trials and meta-analyses, and describe the outcomes that were measured for conditions like fungal infections in the bloodstream (Candidemia) and infection prevention (prophylaxis) in high-risk patients.

Farviron was observed in research scenarios involving widespread fungal conditions, including Candidemia. Research also explored its application in studies examining the incidence rate of these serious infections in specific, high-risk groups. The studies monitored outcomes related to systemic or functional imbalance, such as fever and other general signs of illness, and tracked the frequency of developing a confirmed fungal infection.

Evidence for Use in Central Nervous System Fungal Disease

Studies have examined Farviron's role in the treatment and particularly the long-term maintenance of Cryptococcal Meningitis. This research also explored outcomes capturing phases of heightened symptom activity, such as intense headache and fever. Studies explored measurements related to the removal of the organism from the Cerebrospinal Fluid (CSF) and observed the likelihood of relapse during long-term maintenance phases. Long-term effects are not fully established in all specific subgroups, as follow-up durations were limited in some early research.

Evidence for Use in Mucosal and Localized Yeast Infections

Farviron was evaluated in Randomized, Double-Blind Trials for common conditions involving mucous membranes, such as oral and esophageal thrush, and recurrent vaginal yeast infections. These studies were studied for outcomes related to physical discomfort, such as severe itching, burning, and difficulty swallowing. Studies also tracked the mycological measure, which means measuring outcomes related to the organism removal.

What is Still Uncertain About Farviron's Evidence

The research provides context but describes group patterns, and evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, particularly when comparing highly controlled trials to broader observational data. For many indications, comparative evidence is lacking against newer or alternative therapies. The description of resistance emergence in fungal organisms means that research is ongoing to fully contextualize these patterns.

Key Studies & References Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV (WHO 2022/2018)

Frequently Asked Questions (FAQ)

Common questions about Farviron (FAQ)


Q: Does Farviron have any known long-term risks?

Official regulatory documents describe rare but serious adverse reactions that can occur, such as severe skin conditions and liver toxicity. Studies also indicate that long-term effects are not fully established across all specific patient groups. This means the evidence describes patterns for groups, but not certain outcomes for an individual.


Q: Are there any specific foods or drinks to avoid while taking Farviron?

Official administration guidelines state that this medicine may be taken with or without food. Beyond this general instruction, regulatory documents do not list specific foods or drinks that must be strictly avoided.


Q: What does the research say about Farviron's effects in specific patient groups?

Research has been conducted on the medicine's effects in specific groups, particularly those with systemic, Central Nervous System (CNS), and localized fungal conditions. Regulatory caution is also noted for certain populations, such as older adults and individuals with existing kidney or liver issues.


Q: Why do official documents mention [Specific technical term] regarding Farviron?

Official documents use technical terms, such as Cytochrome P450 14alpha-demethylase and ergosterol, to describe the drug's mechanism. These terms explain that the medicine works by blocking a key enzyme (C14alpha-demethylase) in the fungal cell, which stops the production of the necessary cell membrane component, ergosterol.


Q: Do studies support the use of Farviron in younger adults?

Official documents confirm that the medicine has established indications for adults and children who are 6 months of age and older. The dosing for children is calculated based on body weight, ensuring standardized administration in the pediatric population.


Q: How does Farviron compare to placebo in clinical trials?

Clinical trials often evaluate the medicine against placebo, measuring outcomes such as the mycological measure (which tracks the removal of the fungal organism). These studies also track the patient's experience, including the relief of physical discomfort associated with the infection.


Q: Does Farviron need to be taken at a specific time of day?

According to official administration guidelines, the medicine can be taken at any time of the day. The most important factor is consistency, as it is typically prescribed to be taken once daily.


Q: What kind of monitoring is usually required when starting Farviron?

Regulatory documents emphasize the need for close monitoring in individuals with pre-existing conditions, such as impaired liver or kidney function. Monitoring is also advised when the medicine is used alongside certain other drugs that are known to interact.


Q: Is Farviron a medicine that cures the condition or manages the symptoms?

Official information describes the medicine's activity as fungistatic, meaning it works by inhibiting the growth and reproduction of fungal organisms. This action is intended to relieve and resolve the symptomatic conditions caused by the infection.


Q: What are the signs of a severe allergic reaction to Farviron?

Though rare, serious adverse reactions are documented, and signs may include difficulty breathing, wheezing, or swelling of the face or throat. Severe skin reactions, such as blistering or peeling skin, are also described in official safety information.


Q: What are the key findings from the Phase 3 trials for Farviron?

Research summaries, which include findings from clinical trials, focus on outcomes like the removal of the fungal organism from the body. They also tracked measurements of symptom activity and the likelihood of relapse, particularly during long-term maintenance phases.


Q: Does Farviron have any black box warnings mentioned in the FDA label?

Official FDA labeling includes severe warnings regarding potential risks. These warnings address possible hepatic injury (liver damage) and the potential for fetal harm associated with high-dose, long-term use during the first trimester of pregnancy.


Q: Why is it important to complete the full course of Farviron?

The drug's mechanism is closely tied to the concept of fungal resistance, which involves processes like gene mutations or the use of efflux pumps by the organism. These resistance mechanisms are the focus of ongoing research and are the official rationale for established administration protocols.


Q: Is Farviron known to interact with medicines for blood pressure?

Interactions are documented with certain medicines used for heart or blood pressure conditions. These include common diuretics like Hydrochlorothiazide and some calcium channel blockers. Official documents advise that these combinations may require close monitoring.


Q: Is it normal to feel a little tired when starting Farviron?

Fatigue is not listed among the most common side effects in the regulatory profile. However, official warnings do note that tiredness or fatigue can be a symptom of a very rare but serious adverse reaction called adrenal insufficiency.


Q: How quickly does Farviron typically start working?

According to official patient information, symptoms of the condition generally start to improve after approximately 24 hours following the first dose. However, the time required for full resolution of the infection can vary based on the specific condition being addressed.


Q: What is the longest time someone usually takes Farviron?

The duration of administration varies significantly based on the specific condition being treated, ranging from a single dose for some conditions. For certain serious infections, official documents discuss the use of long-term suppressive therapy.


Q: Will Farviron affect the way my birth control works?

Official information suggests that the medicine may alter the levels of certain hormones, such as levonorgestrel, which is an active ingredient in some hormonal contraceptives. Due to the potential for fetal harm, regulatory documents state that women of childbearing potential should use effective contraception.


Q: What is the difference between Farviron and a traditional antibiotic/antiviral/etc.?

Farviron is classified by regulatory bodies as a synthetic systemic antifungal agent. This means its use is specific to managing infections caused by fungi and yeasts, distinguishing it from antibiotics, which target bacteria, or antivirals, which target viruses.


Q: Can I drive or operate machinery while taking Farviron?

Official warnings state that effects such as dizziness or seizures may occasionally occur in some patients. Regulatory information indicates that this possibility is relevant to the decision to drive vehicles or operate machinery.


Q: Are there any known issues with taking Farviron with vitamins or supplements?

Official patient information states that individuals should ensure their healthcare provider is aware of all products they are taking. This includes all prescribed and over-the-counter medications, as well as natural or herbal remedies and supplements.


Q: How does Farviron interact with alcohol?

Official documents do not typically report a direct drug-alcohol interaction that reduces the medicine's effectiveness. However, because the medicine has the potential to cause hepatic toxicity (liver damage), the potential for hepatic toxicity is a factor to consider regarding alcohol consumption.


Q: Is Farviron considered a Schedule X drug (or equivalent safety classification)?

Official regulatory documents classify Farviron as a prescription-only medication. The medicine is explicitly stated to be not a controlled substance under current scheduling classifications.


Q: I heard Farviron is expensive; is there a generic version available yet?

The active ingredient in Farviron is Fluconazole. This substance is available in FDA-approved generic versions from multiple manufacturers.


Q: Can Farviron be crushed or split if someone has trouble swallowing pills?

The official instructions for the tablet form indicate that it is to be swallowed whole and not cut, broken, or chewed. For patients who have difficulty swallowing, an oral suspension formulation of the medicine is available.


Q: Is Farviron affected by grapefruit?

The medicine is processed through specific enzyme pathways in the body, such as CYP3A4. Regulatory documents note that substances like grapefruit juice can influence these same pathways, which may lead to altered concentrations of co-administered drugs.


Q: What is the difference between the approved uses and the described mechanism of action?

The approved uses describe the specific conditions that regulatory bodies permit the medicine to treat. In contrast, the mechanism of action describes how the drug works at a cellular level, such as by inhibiting key fungal enzymes (fungistasis).


Q: Does Farviron require a special type of prescription?

Farviron is classified as a prescription-only medication. Official regulatory status confirms that it does not require a special type of prescription, such as one associated with controlled substances or restricted-use programs.

How should Farviron be stored and disposed of?

Farviron must be stored according to regulatory requirements to ensure stability.

Requirement Official Regulatory Details
Storage Temperature Store tablets and dry powder for oral suspension below 30 C (86 F).
Protection Do not freeze the medicine. Keep the container tightly closed and protected from light and moisture.
Stability (Suspension) The reconstituted oral suspension must be stored between 5 C and 30 C and any unused portion must be discarded after 2 weeks (14 days).
Safety and Disposal Keep Farviron out of the sight and reach of children. Unused or expired medicine must be disposed of according to local regulations and official advice; do not throw into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Farviron found in:

A-Z Index: